Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ACP-044 for Acute Postoperative Pain Following Orthopedic Surgery (Bunionectomy)

To evaluate the efficacy of ACP-044 compared with placebo in the treatment of acute postoperative pain

Study Overview

• Status: Completed
• Conditions: Acute Postoperative Pain; Bunionectomy
• Intervention / Treatment: Drug: ACP-044 Dose A; Drug: ACP-044 Dose B; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 239
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Anaheim, California, United States, 92801
      • Anaheim Clinical Trials
  • Maryland
    • Pasadena, Maryland, United States, 21122
      • Chesapeake Ambulatory Surgery Center
  • Texas
    • San Antonio, Texas, United States, 78229
      • Endeavor Clinical Trials of San Antonio, TX
  • Utah
    • Salt Lake City, Utah, United States, 84107
      • JBR Cinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female ≥18 and <60 years of age at the time of Screening
• Has a body mass index (BMI) <40 kg/m2
• Able to understand and provide signed informed consent
• Able to complete subject-reported outcome measures
• Is in need of a primary unilateral, first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia and sedation
• Willing to remain inpatient at the study center for 4 days following surgery

Exclusion Criteria:

• Has had a contralateral foot bunionectomy in the past 3 months
• Has a planned concurrent surgical procedure (e.g. bilateral bunionectomy or collateral procedures like hammertoe correction on the surgical foot)
• Any subacute or chronic pain condition or use of a medication that would impair/impact the ability to rate the pain associated with the bunionectomy, in the opinion of the Investigator and Medical Monitor
• Has known or suspected regular use of opioids within the previous 6 months
• Has taken opioids within 24 hours prior to the scheduled surgery or within five half-lives of the drug, whichever is longer
• Has a known or suspected history of drug abuse, a positive drug screen at Screening or Day -1, or a recent (i.e., within the last 5 years) history of alcohol abuse. Subjects using marijuana are not allowed to participate in the study.
• Has taken any aspirin (ASA) or non-steroidal anti-inflammatory drugs (NSAIDs) within 2 days prior to the scheduled surgery or within five half-lives of the drug, whichever is longer
• Has initiated treatment with any medications within 1 month prior to study drug administration that could impact pain control or quantitation of their pain response
• Has been administered systemic steroids within five half-lives or 10 days prior to administration of study drug, whichever is longer
• Has current evidence, or medical history of a serious and/or unstable psychiatric, neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, endocrinologic, or other medical disorder, within the previous 12 weeks prior to Screening and on Day -1, that in the judgment of the Investigator and/or Medical Monitor would jeopardize the safe participation of the subject in the study. Also, subject must not have had a malignancy in the last year, with the exception of nonmetastatic basal cell of the skin or localized carcinoma in situ of the cervix.
• Is judged by the Investigator or the Medical Monitor to be inappropriate for the study

Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Oral dose of placebo
Experimental: Drug - ACP-044 Dose A; ACP-044 Dose A	Drug: ACP-044 Dose A; Oral dose of ACP-044 Dose A
Experimental: Drug - ACP-044 Dose B; ACP-044 Dose B	Drug: ACP-044 Dose B; Oral dose of ACP-044 Dose B

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) of Pain Intensity Scores From Time 0 (When First Dose on Day 1 is Administered) Through 24 Hours	Pain (efficacy) assessments were recorded hourly (±15 minutes) for a 12-hour interval on Day 1 beginning immediately prior to the fifth dose (time 0) administered in the study. Pain assessments were continued every 3 hours during the subsequent 12 hour interval, and then every 6 hours thereafter until 72 hours, then once daily in the morning until the follow-up clinical visit. Pain assessments were also obtained immediately prior to the administration of rescue medication. A 0 to 10 Numeric Rating Scale of Pain Intensity (NRS) was used to assess the subject's pain. Subjects were asked: "Please describe your foot pain at the present time from 0 to 10 where "0" means "no pain at all" and "10" means "the worst pain imaginable." The area under the curve is generated using the following timepoints beginning immediately prior to the fifth dose (time 0): 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, and 24 hours.	0-24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to First Rescue Medication Use After Time 0 (When First Dose on Day 1 is Administered)		0-72 hours
Proportion of Subjects Who Were Opioid Free Through 24 Hours		0-24 hours
Proportion of Subjects Who Were Opioid Free Through 48 Hours		0-48 hours
Proportion of Subjects Who Were Opioid Free Through 72 Hours		0-72 hours
Mean AUC of the NRS of Pain Intensity Scores From Time 0 Through 48 Hours for ACP-044	Pain (efficacy) assessments were recorded hourly (±15 minutes) for a 12-hour interval on Day 1 beginning immediately prior to the fifth dose (time 0) administered in the study. Pain assessments were continued every 3 hours during the subsequent 12 hour interval, and then every 6 hours thereafter until 72 hours, then once daily in the morning until the follow-up clinical visit. Pain assessments were also obtained immediately prior to the administration of rescue medication. A 0 to 10 Numeric Rating Scale of Pain Intensity (NRS) was used to assess the subject's pain. Subjects were asked: "Please describe your foot pain at the present time from 0 to 10 where "0" means "no pain at all" and "10" means "the worst pain imaginable." The area under the curve is generated using the following timepoints beginning immediately prior to the fifth dose (time 0): 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, 24, 30, 36, 42, and 48 hours.	0-48 hours
Mean AUC of the NRS of Pain Intensity Scores From Time 0 Through 72 Hours for ACP-044	Pain (efficacy) assessments were recorded hourly (±15 minutes) for a 12-hour interval on Day 1 beginning immediately prior to the fifth dose (time 0) administered in the study. Pain assessments were continued every 3 hours during the subsequent 12 hour interval, and then every 6 hours thereafter until 72 hours, then once daily in the morning until the follow-up clinical visit. Pain assessments were also obtained immediately prior to the administration of rescue medication. A 0 to 10 Numeric Rating Scale of Pain Intensity (NRS) was used to assess the subject's pain. Subjects were asked: "Please describe your foot pain at the present time from 0 to 10 where "0" means "no pain at all" and "10" means "the worst pain imaginable." The area under the curve is generated using the following timepoints beginning immediately prior to the fifth dose (time 0): 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, 60, 66, and 72 hours.	0-72 hours
Mean AUC of the NRS of Pain Intensity Scores From Time 0 Through 4 Hours for ACP-044	Pain (efficacy) assessments were recorded hourly (±15 minutes) for a 12-hour interval on Day 1 beginning immediately prior to the fifth dose (time 0) administered in the study. Pain assessments were continued every 3 hours during the subsequent 12 hour interval, and then every 6 hours thereafter until 72 hours, then once daily in the morning until the follow-up clinical visit. Pain assessments were also obtained immediately prior to the administration of rescue medication. A 0 to 10 Numeric Rating Scale of Pain Intensity (NRS) was used to assess the subject's pain. Subjects were asked: "Please describe your foot pain at the present time from 0 to 10 where "0" means "no pain at all" and "10" means "the worst pain imaginable." The area under the curve is generated using the following timepoints beginning immediately prior to the fifth dose (time 0): 0, 1, 2, 3, and 4 hours.	0-4 hours
Mean AUC of the NRS of Pain Intensity Scores From Time 0 Through 6 Hours for ACP-044	Pain (efficacy) assessments were recorded hourly (±15 minutes) for a 12-hour interval on Day 1 beginning immediately prior to the fifth dose (time 0) administered in the study. Pain assessments were continued every 3 hours during the subsequent 12 hour interval, and then every 6 hours thereafter until 72 hours, then once daily in the morning until the follow-up clinical visit. Pain assessments were also obtained immediately prior to the administration of rescue medication. A 0 to 10 Numeric Rating Scale of Pain Intensity (NRS) was used to assess the subject's pain. Subjects were asked: "Please describe your foot pain at the present time from 0 to 10 where "0" means "no pain at all" and "10" means "the worst pain imaginable." The area under the curve is generated using the following timepoints beginning immediately prior to the fifth dose (time 0): 0, 1, 2, 3, 4, 5, and 6 hours.	0-6 hours
Mean AUC of the NRS of Pain Intensity Scores From Time 0 Through 12 Hours for ACP-044	Pain (efficacy) assessments were recorded hourly (±15 minutes) for a 12-hour interval on Day 1 beginning immediately prior to the fifth dose (time 0) administered in the study. Pain assessments were continued every 3 hours during the subsequent 12 hour interval, and then every 6 hours thereafter until 72 hours, then once daily in the morning until the follow-up clinical visit. Pain assessments were also obtained immediately prior to the administration of rescue medication. A 0 to 10 Numeric Rating Scale of Pain Intensity (NRS) was used to assess the subject's pain. Subjects were asked: "Please describe your foot pain at the present time from 0 to 10 where "0" means "no pain at all" and "10" means "the worst pain imaginable." The area under the curve is generated using the following timepoints beginning immediately prior to the fifth dose (time 0): 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours.	0-12 hours
Mean AUC of the NRS of Pain Intensity Scores From 24 Through 48 Hours for ACP-044	Pain (efficacy) assessments were recorded hourly (±15 minutes) for a 12-hour interval on Day 1 beginning immediately prior to the fifth dose (time 0) administered in the study. Pain assessments were continued every 3 hours during the subsequent 12 hour interval, and then every 6 hours thereafter until 72 hours, then once daily in the morning until the follow-up clinical visit. Pain assessments were also obtained immediately prior to the administration of rescue medication. A 0 to 10 Numeric Rating Scale of Pain Intensity (NRS) was used to assess the subject's pain. Subjects were asked: "Please describe your foot pain at the present time from 0 to 10 where "0" means "no pain at all" and "10" means "the worst pain imaginable." The area under the curve is generated using the following timepoints beginning immediately prior to the fifth dose (time 0): 24, 30, 36, 42, and 48 hours.	24-48 hours
Mean AUC of the NRS of Pain Intensity Scores From Time 48 Through 72 Hours for ACP-044	Pain (efficacy) assessments were recorded hourly (±15 minutes) for a 12-hour interval on Day 1 beginning immediately prior to the fifth dose (time 0) administered in the study. Pain assessments were continued every 3 hours during the subsequent 12 hour interval, and then every 6 hours thereafter until 72 hours, then once daily in the morning until the follow-up clinical visit. Pain assessments were also obtained immediately prior to the administration of rescue medication. A 0 to 10 Numeric Rating Scale of Pain Intensity (NRS) was used to assess the subject's pain. Subjects were asked: "Please describe your foot pain at the present time from 0 to 10 where "0" means "no pain at all" and "10" means "the worst pain imaginable." The area under the curve is generated using the following timepoints beginning immediately prior to the fifth dose (time 0): 48, 54, 60, 66, and 72 hours.	48-72 hours
Rescue Medication Taken During 0-24 Hours	Number of instances of rescue medication taken during first 24 hours.	0-24 hours
Rescue Medication Taken During 24-48 Hours	Number of instances of rescue medication taken during 24-48 hours.	24-48 hours
Rescue Medication Taken During 48-72 Hours	Number of instances of rescue medication taken during 48-72 hours.	48-72 hours
Rescue Medication Taken During 0-48 Hours	Number of instances of rescue medication taken during first 48 hours.	0-48 hours
Rescue Medication Taken During 0-72 Hours	Number of instances of rescue medication taken during first 72 hours.	0-72 hours
Proportion of Subjects Who Did Not Use Rescue Medication Through 24 Hours		0-24 hours
Proportion of Subjects Who Did Not Use Rescue Medication Through 48 Hours		0-48 hours
Proportion of Subjects Who Did Not Use Rescue Medication Through 72 Hours		0-72 Hours
Proportion of Subjects Who Are Pain Free (NRS ≤2) at 24 Hours		0-24 hours
Proportion of Subjects Who Are Pain Free (NRS ≤2) at 48 Hours		0-48 hours
Proportion of Subjects Who Are Pain Free (NRS ≤2) at 72 Hours		0-72 hours
Number of Hours Subjects Are Pain Free (NRS ≤2)		0-72 hours
Proportion of Subjects Who Were Opioid Free During 24-48 Hours		24-48 hours
Proportion of Subjects Who Were Opioid Free During 48-72 Hours		48-72 hours
Global Evaluation of Study Drug Just Before Time of First Rescue Medication Relative to Time 0 (When First Dose on Day 1 is Administered)	5 point scale (0-4) with categories of 0-poor, 1-fair, 2-good, 3-very good, or 4-excellent	First rescue medication dose, up to 24 hours post first dose.
Global Evaluation of Study Drug at the End of 24 Hours Relative to Time 0 (When First Dose on Day 1 is Administered)	5 point scale (0-4) with categories of 0-poor, 1-fair, 2-good, 3-very good, or 4-excellent	24 hours
Global Evaluation of Study Drug at the End of 48 Hours Relative to Time 0 (When First Dose on Day 1 is Administered)	5 point scale (0-4) with categories of 0-poor, 1-fair, 2-good, 3-very good, or 4-excellent	48 hours
Global Evaluation of Study Drug at the End of 72 Hours Relative to Time 0 (When First Dose on Day 1 is Administered)	5 point scale (0-4) with categories of 0-poor, 1-fair, 2-good, 3-very good, or 4-excellent	72 hours

Collaborators and Investigators

• Sponsor: ACADIA Pharmaceuticals Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 29, 2021
• Primary Completion (Actual): February 11, 2022
• Study Completion (Actual): March 14, 2022

Study Registration Dates

• First Submitted: April 19, 2021
• First Submitted That Met QC Criteria: April 21, 2021
• First Posted (Actual): April 22, 2021

Study Record Updates

• Last Update Posted (Actual): May 3, 2023
• Last Update Submitted That Met QC Criteria: April 8, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Postoperative Complications; Pain; Neurologic Manifestations; Pain, Postoperative
• Other Study ID Numbers: ACP-044-004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No